Alzheimer's Patients in Switzerland Face Limited Options as Regulator Approves Only One New Drug

Swiss patients face a stark new reality: while the rest of the world moves forward with multiple treatment options, Switzerland stands alone. In a decisive move that fractures the landscape of Alzheimer's care, Swissmedic has approved Eli Lilly's Kisunla (donanemab) but effectively shut the door on Leqembi (lecanemab), a drug currently available in over 50 nations. This regulatory split decision leaves Switzerland as a conspicuous outlier in the global healthcare community.

The timeline reveals a critical divergence. While the US regulator gave the green light to Leqembi back in July 2023, Swiss doctors endured a grueling two-and-a-half-year wait, only to receive a mixed verdict in early 2026. The approval of Kisunla on January 22 offers a glimmer of hope, but the subsequent withdrawal of the Leqembi application just one week later signals a troubling limitation on patient choice. As major markets embrace a multi-drug approach to combat cognitive decline, Switzerland's restrictive regulatory environment has forced a contraction of options, leaving patients and families to navigate a complex disease with significantly fewer tools than their international counterparts.

The urgency of this regulatory bottleneck cannot be overstated when viewed against the staggering scale of the crisis. Switzerland is currently home to an estimated 161,000 people living with dementia, a number that looms large over the healthcare system. With Alzheimer’s disease accounting for a massive 60-70% of these cases, the demand for effective treatment is not just growing—it is exploding.

Globally, the situation is even more dire. Approximately 32 million people are currently afflicted by Alzheimer's, and with the relentless aging of the population, experts predict this figure will triple by 2050. This demographic shift represents a ticking time bomb for healthcare policy. Every delayed approval and every withdrawn application narrows the window of opportunity for thousands of patients desperate to slow the progression of this debilitating condition. In this context, the availability of only a single new therapeutic option in Switzerland appears dangerously insufficient to meet the surging tide of demand.

The sudden exit of Leqembi from the Swiss regulatory process was not a mere administrative formality; it was a calculated rejection of Swissmedic's terms. Japanese manufacturer Eisai pulled the plug on its application on January 29, citing irreconcilable differences over patient eligibility. The company explicitly stated that Swissmedic's "restrictive" conditions would have slashed the eligible patient population to a fraction of what is standard in the rest of Europe.

"Withdrawal of the application was the only feasible path forward under these conditions," an Eisai spokesperson declared, drawing a hard line in the sand. This corporate pushback highlights a fierce tension between regulatory caution and pharmaceutical viability. By insisting on stricter parameters than other global regulators, Swissmedic inadvertently created an environment where a major pharmaceutical player deemed the Swiss market unviable for its flagship drug. The result is a significant blow to Swiss healthcare autonomy, where regulatory stringency has directly resulted in a reduction of available medical innovation.

For the medical community, the approval of Kisunla is a bittersweet victory. While doctors finally possess a tool to attack the underlying amyloid plaques that characterize Alzheimer's, the absence of a second option limits their tactical flexibility. Bogdan Draganski, head of the Memory Clinic at Inselspital Bern, captured the sentiment of the profession: "The approval of Kisunla is positive news... But of course it would have been nice to have both treatments. The more choice the better."

These drugs represent the first genuine breakthroughs in decades, capable of slowing cognitive decline rather than merely masking symptoms. However, they are not cures, and they come with serious potential side effects that vary from patient to patient. Relying on a single drug creates a vulnerability; if a patient cannot tolerate Kisunla, there is now no approved alternative in Switzerland. As the country moves forward with only one weapon in its arsenal, the pressure on Kisunla to perform is immense, and the scrutiny on Swissmedic's conservative approach will only intensify as patients look across the border to see what they are missing.